Tandem Diabetes Care (Nasdaq:TNDM) announced today that it appointed two new independent members to its board of directors. Myoung Cha and Joao Malagueira have been named to the San Diego-based automated insulin delivery technology developer’s board, effective yesterday. “We welcome Joao and Myoung to our board of directors at this exciting stage in Tandem’s evolution,” […]
Senseonics wins CE mark approval for 180-day Eversense E3 CGM
Senseonics (NYSE:SENS) announced today that it received CE mark for the next-generation Eversense E3 CGM system. Germantown, Maryland-based Senseonics offered a previous-generation continuous glucose monitor (CGM) with a 90-day wear time. Its next-generation Eversense E3 can be used for up to six months (180 days). Europe already had a 180-day Senseonics CGM system available (Eversense […]
GI Dynamics EndoBarrier meets endpoints in diabetes, obesity study
GI Dynamics today announced the results of a study of its EndoBarrier system that met efficacy and safety endpoints. Boston-based GI Dynamics designed its EndoBarrier endoscopically delivered device therapy as a non-surgical, alternative treatment for type 2 diabetes and obesity for patients who do not have adequate control of their conditions through their current medication and […]
Owen Mumford appoints new director of R&D
Owen Mumford announced today that it appointed Bal Johal as its director of research and development, effective next month. Johal will become the director of R&D for the Woodstock, United Kingdom-based developer of medical devices, including the Aidaptus auto-injector, on July 4, 2022. She has most recently served as VP of product development, quality, regulatory […]
Fresenius Kabi expands compatibility of radio frequency tagged medication
Fresenius Kabi announced today that its portfolio of radio frequency tagged medications is now compatible with an AmerisourceBergen offering. Lake Zurich, Illinois-based Fresenius Kabi’s growing +RFID portfolio now has compatibility with AmerisourceBergen’s medication tray solution for helping hospitals improve medication inventory visibility and tracking using advanced radiofrequency identification (RFID) technology. Get the full story at […]
InfuSystem, Ventis Pharma enter pain management marketing deal
InfuSystem (NSYE:INFU) announced today that it entered into a national sales and marketing agreement with Ventis Pharma. Rochester Hills, Michigan-based InfuSystem’s partnership with Ventis will focus on sales and marketing for the latter’s patented Endura-Kit brand of Enduracaine, a local anesthetic compound. The kit consists of three non-opioid drugs: tetracaine, lidocaine and epinephrine. Ventis Pharma […]
Data shows cost benefits with Pear Therapeutics digital therapeutic for opioid use disorder
Pear Therapeutics (Nasdaq:PEAR) today shared real-world data highlighting low costs with its reSET-O prescription digital therapeutic (PDT). Boston-based Pear Therapeutics’ reSET-O represents the only FDA-authorized PDT for the treatment of opioid use disorder (OUD). According to a news release, results from a 12-month, real-world data study of reSET-O demonstrated reduced healthcare resource utilization and associated […]
Early study supports experimental hydrogel injection for chronic low back pain
A study demonstrated that an experimental hydrogel formulation was safe and effective in substantially relieving chronic low back pain. Research presented at the Society of Interventional Radiology Annual Scientific Meeting in Boston supported the hydrogel, which was injected into spinal discs in an effort to relieve chronic low back pain caused by degenerative disc disease […]
Dexcom quadruples number of shares
Dexcom (Nasdaq:DXCM) recently filed a restated certificate of incorporation to effect a four-for-one forward stock split. Shares of DXCM were down 0.9% at $293.85 per share at market close on Friday, June 10. Following the stock split, shares moved down 75.33% to $72.50 before the market opened this morning. At market open, shares were down […]
Data supports Beta Bionics’ iLet bionic pancreas
Beta Bionics announced today that a trial of its iLet bionic pancreas met key endpoints, including reduced HbA1c. Dr. Roy W. Beck and clinical investigators presented the results of the multi-center, randomized Insulin-Only Bionic Pancreas Pivotal Trial (IO BPPT) at the American Diabetes Association (ADA) 82nd Scientific Sessions in New Orleans. Read: The biggest stories […]
